CN114728944A - 血管紧张素ii受体拮抗剂与nep抑制剂的复合物及其制备方法 - Google Patents

血管紧张素ii受体拮抗剂与nep抑制剂的复合物及其制备方法 Download PDF

Info

Publication number
CN114728944A
CN114728944A CN202080076793.9A CN202080076793A CN114728944A CN 114728944 A CN114728944 A CN 114728944A CN 202080076793 A CN202080076793 A CN 202080076793A CN 114728944 A CN114728944 A CN 114728944A
Authority
CN
China
Prior art keywords
complex
ahu377
allisartan isoproxil
angiotensin
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080076793.9A
Other languages
English (en)
Other versions
CN114728944B (zh
Inventor
李松
许文杰
程冲
孙晶超
华怀杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Salubris Pharmaceuticals Co Ltd
Original Assignee
Shenzhen Salubris Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Salubris Pharmaceuticals Co Ltd filed Critical Shenzhen Salubris Pharmaceuticals Co Ltd
Publication of CN114728944A publication Critical patent/CN114728944A/zh
Application granted granted Critical
Publication of CN114728944B publication Critical patent/CN114728944B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

提供了一系列具有双重作用的超分子络合物(复合物)，该超分子络合物(复合物)包含具有血管紧张素II受体(AT1)阻断作用的化合物、脑啡肽酶抑制剂(NEPi)、药学上可接受的阳离子。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN202080076793.9A 2019-11-11 2020-11-09 血管紧张素ii受体拮抗剂与nep抑制剂的复合物及其制备方法 Active CN114728944B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019110926076 2019-11-11
CN201911092607 2019-11-11
PCT/CN2020/127415 WO2021093697A1 (zh) 2019-11-11 2020-11-09 血管紧张素ii受体拮抗剂与nep抑制剂的复合物及其制备方法

Publications (2)

Publication Number Publication Date
CN114728944A true CN114728944A (zh) 2022-07-08
CN114728944B CN114728944B (zh) 2023-09-15

Family

ID=75911785

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080076793.9A Active CN114728944B (zh) 2019-11-11 2020-11-09 血管紧张素ii受体拮抗剂与nep抑制剂的复合物及其制备方法

Country Status (2)

Country Link
CN (1) CN114728944B (zh)
WO (1) WO2021093697A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115443272B (zh) * 2020-08-17 2023-11-17 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的心衰应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105982891A (zh) * 2015-01-30 2016-10-05 王召印 阿利沙坦脂和脑啡肽酶抑制剂或其前药的药物组合物
WO2017125031A1 (zh) * 2016-01-20 2017-07-27 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105963296B (zh) * 2015-03-12 2020-01-21 深圳信立泰药业股份有限公司 一种含有阿利沙坦酯或其盐或其水解产物或其水解产物盐的药物组合物及其用途
CN106146472A (zh) * 2015-04-15 2016-11-23 苏州朗科生物技术有限公司 一种双重作用的阿利沙坦复合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105982891A (zh) * 2015-01-30 2016-10-05 王召印 阿利沙坦脂和脑啡肽酶抑制剂或其前药的药物组合物
WO2017125031A1 (zh) * 2016-01-20 2017-07-27 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法

Also Published As

Publication number Publication date
CN114728944B (zh) 2023-09-15
WO2021093697A1 (zh) 2021-05-20

Similar Documents

Publication Publication Date Title
CN108473474B (zh) 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法
US20210002202A1 (en) Substituted Aromatic Compounds and Pharmaceutical Uses Thereof
JP2020203936A (ja) バルサルタンおよびａｈｕ−３７７を含む三ナトリウム塩超分子複合体の新規な結晶形及びその製造方法
ES2441800T3 (es) Sales de ácido 3-pentilfenilacético y usos farmacéuticos de las mismas
JP5981940B2 (ja) アジルサルタン有機アミン塩、その製造方法及び使用
CN113286789B (zh) 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途
KR20230121761A (ko) 인테그린 억제제 및 그의 용도
CN114728944A (zh) 血管紧张素ii受体拮抗剂与nep抑制剂的复合物及其制备方法
CN112638903A (zh) 舒欣啶盐
WO2019033969A1 (zh) 替米沙坦与氢氯噻嗪的共晶
JP2014516348A (ja) ガリウム錯体、医薬組成物および使用方法
WO2022111493A1 (zh) Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途
JP6767382B2 (ja) トピロキソスタットの新規結晶形及びその製造方法
CN110066258A (zh) 噻唑-5-甲酸衍生物及其制备方法与应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Area A, 4th Floor, Digital Peninsula, No. 2, Hongliu Road, Fubao Community, Fubao Street, Futian District, Shenzhen, Guangdong, 518017

Applicant after: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd.

Address before: 518040 37th floor, chegongmiao Lvjing Plaza, 6009 Shennan Avenue, Futian District, Shenzhen City, Guangdong Province

Applicant before: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd.

GR01 Patent grant
GR01 Patent grant